MIND MEDICINE MINDMED INC (MNMD)

CA60255C8850 - Common Stock

8.8  -0.11 (-1.23%)

Fundamental Rating

1

MNMD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. MNMD has a bad profitability rating. Also its financial health evaluation is rather negative. MNMD is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MNMD has reported negative net income.
In the past year MNMD has reported a negative cash flow from operations.
MNMD had negative earnings in each of the past 5 years.
In the past 5 years MNMD always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -76.87%, MNMD is not doing good in the industry: 70.92% of the companies in the same industry are doing better.
The Return On Equity of MNMD (-122.53%) is worse than 64.29% of its industry peers.
Industry RankSector Rank
ROA -76.87%
ROE -122.53%
ROIC N/A
ROA(3y)-55.67%
ROA(5y)-49.46%
ROE(3y)-73.83%
ROE(5y)-61.54%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, MNMD has more shares outstanding
MNMD has more shares outstanding than it did 5 years ago.
MNMD has a worse debt/assets ratio than last year.

2.2 Solvency

MNMD has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MNMD has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: MNMD outperforms 59.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 3.22 indicates that MNMD has no problem at all paying its short term obligations.
MNMD's Current ratio of 3.22 is in line compared to the rest of the industry. MNMD outperforms 51.02% of its industry peers.
MNMD has a Quick Ratio of 3.22. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.22, MNMD is in line with its industry, outperforming 54.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 3.22

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNMD have decreased strongly by -20.83% in the last year.
EPS 1Y (TTM)-20.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-268.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

MNMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.25% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.92%
EPS Next 2Y16.35%
EPS Next 3Y9.9%
EPS Next 5Y24.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MNMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.35%
EPS Next 3Y9.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (4/19/2024, 8:35:01 AM)

8.8

-0.11 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap618.38M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.87%
ROE -122.53%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.22
Quick Ratio 3.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-20.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y